Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
A Venn diagram representing RNA
2023-10-31

A. Venn diagram representing RNA-seq data that show the number of gene overlaps in GFP and HepKO livers after chronic PF-06409577 dosing. B. Top canonical pathways that changed according to Ingenuity Pathway Analysis after chronic PF-06409577 dosing. C. Fibrosis-related genes that were altered in GF
-
In the present study AP
2023-10-31

In the present study, AP31-B preferentially released hydrophobic prostaglandin receptor such as leucine and alanine from N-terminal of peptide (Fig. 4). The debittering ability of AP31-B seemed to depend on such substrate specificity, but additional tests against other hydrophobic amino acids are n
-
br Materials and methods br
2023-10-31

Materials and methods Results Discussion The novel and central finding of the current study is that endothelial 12/15-LO rather than the monocytic/macrophagic 12/15-LO has a critical role in hyperglycemia-induced leukocyte adhesion and retinal endothelial barrier dysfunction. The following
-
Recently rather than predicting categorical
2023-10-31

Recently, rather than predicting categorical variables as in classification, several studies begin to estimate continuous clinical variables from GSK180 receptor images. Therefore, instead of classify a subject into binary or multiple pre-determined categories or stages of the disease, regression fo
-
br Conflict of interest br Introduction Colorectal
2023-10-31

Conflict of interest Introduction Colorectal cancer (CRC) is one of the major cause of tumor-related morbidity and mortality worldwide. Poor prognosis and consequences of its metastatic spread make CRC the second most common cause of cancer-related deaths in western countries [1]. Apart from o
-
There are two ways to transport FFAs
2023-10-31

There are two ways to transport FFAs into cells. First by passive diffusion. Second as the putative long-chain fatty p-Cresyl sulfate transporters are proposed, CD36 the plasma membrane-associated fatty acid-binding protein (FABPpm) and fatty acid transport proteins (FATP) [11], where CD36 is respon
-
Our previous work fails to show
2023-10-31

Our previous work fails to show any maternal effect with blockade of 5-HT2A receptor, as acute and repeated treatment of MDL100907 does not alter maternal behavior at the behaviorally active doses (Chen et al., 2014). In the present study, MDL100907 pretreatment attenuated the maternal disruptive ef
-
Salivary amylase activity was not significantly different be
2023-10-31

Salivary α-amylase activity was not significantly different between bitches with pyometra and healthy bitches, and there were no significant changes after ovariohysterectomy, similar to chromogranin A (Jitpean et al., 2015). Therefore, it is postulated that the SAM axis is not activated in bitches w
-
br Disclaimer br Conflicts of interest br Role of
2023-10-31

Disclaimer Conflicts of interest Role of the Sponsor Acknowledgements Funding/support: This project was supported by a grant from the Department of Surgery (R5129), Western University and by the Institute for Clinical Evaluative Sciences (ICES) Western site. ICES is funded by an annual g
-
br Materials and Methods br Author Contributions
2023-10-31

Materials and Methods Author Contributions Conflicts of Interest Acknowledgments This study was funded by the NIH Common Fund (UH2TR000943) through the Office of Strategic Coordination/Office of the NIH Director, an NCI/NIH grant (1R21CA199050), the MD Anderson Cancer Center support gran
-
The earliest appearance of tumors occurred at months and the
2023-10-31

The earliest appearance of tumors occurred at 12 months and the latest at 24 months, with an average onset at 18 months (Fig. 1B). This would be roughly equivalent to cancer presenting in a patient between 60 and 70 years of age. In transgenic animals, autotaxin Talabostat mesylate was relatively i
-
To elucidate whether membrane fluidity changes could impact
2023-10-31

To elucidate whether membrane fluidity changes could impact on signaling pathways, we examined the effects of Rh2 on the activation of Akt, a lipid raft-associated protein kinase, which promotes cell survival and blocks the apoptotic pathways. Upon pretreatment with 5 mM MβCD and in the absence of R
-
How do increased levels of ammonia as
2023-10-30

How do increased levels of ammonia as observed in clinical HE constrain synaptic plasticity? Numerous studies have investigated the modulation of signal transduction pathways activated in LTP or LTD irrespective of being necessary or sufficient for changes in synaptic efficacy (Wen et al., 2013). Ye
-
ganciclovir mg LOXs and CYPs are a series of iron
2023-10-30

LOXs and CYPs are a series of iron-containing enzymes that metabolize arachidonic ganciclovir mg to form biologically active products, such as epoxyeicosatrienoic acids (EETs) hydroperoxyeicosatetraenoic acids (HETEs), prostaglandins, leukotrienes and thromboxanes [6]. Among these mediators, 12/15L
-
br Development of lorlatinib from crizotinib to
2023-10-30

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
15674 records 247/1045 page Previous Next First page 上5页 246247248249250 下5页 Last page